- Radioimmunotherapy with 90Y-radiolabelled anti-CD20 monoclonal antibody in patients with B-cell non-Hodgkin´s lymphoma +3Publication without faculty affiliation
- Anti-Lymphoma Efficacy Comparison of Anti-CD20 Monoclonal Antibody-Targeted and Non-Targeted Star-Shaped Polymer-Prodrug Conjugates2015 | First Faculty of Medicine
- Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients2015 | Publication without faculty affiliation
- Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients2015 | Faculty of Medicine in Hradec Králové
- Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis A phase 2 study2014 | First Faculty of Medicine
- Single-nucleotide Fc gamma receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma2021 | First Faculty of Medicine
- Ofatumumab - a new high-efficacy treatment for relapsing forms of multiple sclerosis2021 | Faculty of Medicine in Hradec Králové
- Maintenance treatment with rituximab in nonhodgkin's lymphoma2012 | Faculty of Medicine in Hradec Králové
- Ofatumumab - a highly effective therapy for relapsing-remitting multiple sclerosis available in the first line2022 | Faculty of Medicine in Hradec Králové
- Ofatumumab and siponimod in the treatment of multiple sclerosis - case reports2022 | Faculty of Medicine in Hradec Králové
- Maintenance therapy with rituximab for non-Hodgkin's lymphoma - opportunities in 20102010 | Faculty of Medicine in Hradec Králové
- Subcutaneous administration of rituximab in B-non-Hodgkin's lymphoma patients2014 | Publication without faculty affiliation
- Patient with follicular lymphoma and subcutaneous administration of rituximab2014 | Faculty of Medicine in Hradec Králové
- Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab2019 | First Faculty of Medicine
- Ofatumumab2021 | First Faculty of Medicine
- Multiple sclerosis patient suitable for the treatment with ofatumumab2022 | Faculty of Medicine in Hradec Králové
- Therapy of elderly/comorbid patients with chronic lymphocytic leukemia2013 | Faculty of Medicine in Hradec Králové
- Overcoming resistance to rituximab in relapsed non-Hodgkin lymphomas by antibody-polymer drug conjugates actively targeted by anti-CD38 daratumumab2020 | First Faculty of Medicine
- Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study2024 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Faculty of Medicine in Pilsen, Third Faculty of Medicine, Faculty of Pharmacy in Hradec Králové
- Anti-CD38 Therapy with Daratumumab for Relapsed/Refractory CD20-Negative Diffuse Large B-Cell Lymphoma2020 | First Faculty of Medicine, Second Faculty of Medicine
- Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study2022 | Faculty of Medicine in Hradec Králové
- Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives2022 | First Faculty of Medicine
- Modern approach to the treatment of chronic lymphocytic leukemia2023 | Faculty of Medicine in Hradec Králové
- Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study2015 | Faculty of Medicine in Hradec Králové
- Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment2021 | First Faculty of Medicine
- Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma2017 | Publication without faculty affiliation
- Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy2019 | First Faculty of Medicine